cd19 car-t therapy scleroderma
The Day This Trial Changed Chronic Disease Management
Yes, a single infusion of CD19 CAR-T cells can halt disease progression in severe scleroderma, according to early CASTLE data. Patients who had exhausted every standard drug showed stabilisation and, in some cases, reversal of organ damage within weeks of treatment. In 2026 the CASTLE basket trial began enrolling patients